Sharon Bio-Medicine Key Ratios
NSE: SHARONBIO | BSE: 532908
₹3.30
₹-0.15
(-4.35%)
As on 28-Mar-2019IST
Market cap
₹2 Cr
Revenue (TTM)
₹240 Cr
P/E Ratio
0.1
P/B Ratio
-0.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -23.39 | -11.12 | 3.50 | 4.43 | 8.67 |
| EBIT | -86.10 | -71.30 | -2.42 | -1.52 | 33.69 |
| Net Profit | -80.92 | -61.42 | 7.54 | 4.07 | 16.95 |
| EPS | -80.92 | -61.42 | 7.54 | 107.64 | 42.51 |
| Book Value | -- | -- | 85.09 | 229.73 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| 9.32 | -- | -- | 17.64 | 9.32 |
| Net Margin
| 21.04 | -- | 16.28 | 11.29 | 35.56 |
| Return on equity
| 40.53 | -- | 58.92 | 62.67 | 0.00 |
| Return on Capital
| 34.84 | -- | 36.08 | 25.24 | 43.18 |
| Return on Assets
| 23.23 | -- | 19.68 | 11.98 | 38.01 |
| Debt to Equity (x)
| -- | -- | 0.96 | 2.52 | 5.60 |
Profitability
ROCE
36.08
Higher than Peers by 21.18
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
36.08
|
25.24
|
43.18
|
9.79
|
4.32
|
|
Peer Median
|
14.90
|
14.72
|
18.85
|
11.60
|
--
|
ROE
58.92
Higher than Peers by 46.15
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
58.92
|
62.67
|
--
|
--
|
--
|
|
Peer Median
|
12.77
|
11.67
|
14.92
|
11.46
|
--
|
ROA
19.68
Higher than Peers by 12.59
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
19.68
|
11.98
|
38.01
|
6.44
|
3.46
|
|
Peer Median
|
7.09
|
7.86
|
9.06
|
6.44
|
--
|
EBIT Margin
21.37
Higher than Peers by 7.30
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
21.37
|
17.64
|
9.32
|
7.60
|
7.95
|
|
Peer Median
|
14.07
|
15.03
|
14.71
|
12.37
|
--
|
Net Margin
16.28
Higher than Peers by 7.73
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
16.28
|
11.29
|
35.56
|
9.66
|
9.24
|
|
Peer Median
|
8.54
|
9.33
|
8.49
|
10.02
|
--
|
Cash Profit Margin
20.32
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
20.32
|
16.18
|
52.62
|
14.78
|
15.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
21.76
Higher than Peers by 8.72
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
21.76
|
3.82
|
-1.04
|
2.03
|
-25.67
|
|
Peer Median
|
13.04
|
10.27
|
11.85
|
9.08
|
--
|
EBIT Growth
47.45
Higher than Peers by 30.28
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
47.45
|
96.54
|
21.34
|
-2.42
|
--
|
|
Peer Median
|
17.18
|
24.15
|
28.00
|
-3.12
|
--
|
Net Profit Growth
76.94
Higher than Peers by 52.10
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
76.94
|
-74.36
|
375.65
|
7.53
|
105.91
|
|
Peer Median
|
24.83
|
30.29
|
36.51
|
-0.85
|
--
|
EPS Growth
76.94
Higher than Peers by 59.13
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
76.94
|
-74.36
|
--
|
7.54
|
205.00
|
|
Peer Median
|
17.80
|
24.50
|
--
|
-6.82
|
--
|
Book Value Growth
85.09
--
Year on year growth in book value per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
85.09
|
94.23
|
104.09
|
5.49
|
-218.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.96
Higher than Peers by 0.75
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
0.96
|
2.52
|
5.60
|
-1.35
|
-1.27
|
|
Peer Median
|
0.21
|
0.23
|
0.20
|
0.15
|
--
|
Short term debt to equity ratio
0.25
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
0.25
|
--
|
--
|
-0.44
|
-0.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.23
Lower than Peers by 0.60
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
1.23
|
2.43
|
2.26
|
0.51
|
0.45
|
|
Peer Median
|
1.83
|
1.79
|
1.96
|
2.08
|
--
|
Quick Ratio
0.74
Lower than Peers by 0.46
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
0.74
|
1.45
|
1.46
|
0.40
|
0.33
|
|
Peer Median
|
1.20
|
1.47
|
1.44
|
1.58
|
--
|
Interest Coverage
7.04
Lower than Peers by 1.13
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
7.04
|
3.68
|
7.90
|
307.53
|
161.10
|
|
Peer Median
|
8.17
|
9.42
|
8.58
|
15.41
|
--
|
Operating Efficiency
Debtors to sales
21.27
Lower than Peers by 3.88
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
21.27
|
20.31
|
14.69
|
13.57
|
14.27
|
|
Peer Median
|
25.14
|
25.82
|
26.12
|
22.96
|
--
|
Asset Turnover
1.15
Higher than Peers by 0.42
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
1.15
|
1.02
|
0.80
|
0.65
|
0.37
|
|
Peer Median
|
0.73
|
0.75
|
0.77
|
0.65
|
--
|
Receivable days
69.26
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
69.26
|
62.90
|
51.84
|
50.29
|
203.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
58.25
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
58.25
|
56.24
|
61.83
|
77.23
|
215.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
85.50
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
85.50
|
95.46
|
155.83
|
172.58
|
180.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
42.01
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
42.01
|
23.69
|
-42.16
|
-45.06
|
238.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
43.99
|
39.70
|
33.48
|
37.74
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.66
|
3.72
|
4.21
|
3.22
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.16
|
0.21
|
0.57
|
--
|
EV/EBITDA
1.21
Lower than Peers by 28.15
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
1.21
|
2.39
|
1.54
|
25.94
|
26.77
|
|
Peer Median
|
29.36
|
30.23
|
29.90
|
28.81
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
Sharon Bio-Medicine
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5,258
|
4,851
|
2,099
|
15,272
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
